Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Hoffmann-La Roche
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Adult patients, \>/= 18 years of age
Moderate to severe rheumatoid arthritis according to the revised (1987) ACR criteria
Patients in whom the treating physician has made the decision to commence RoActemra/Actemra treatment in accordance with the local label; this can include patients who have received RoActemra/Actemra treatment within 8 weeks prior to the enrolment visit
Patients who for any reason do not take methotrexate and the treating physician has made a decision to prescribe RoActemra/Actemra as monotherapy
Patients who were previously on a TNF inhibitor as monotherapy, and the treating physician has made a decision to prescribe RoActemra/Actemra as monotherapy
Concomitant treatment with corticosteroids (orally and intra-articularly) and/or NSAIDs is allowed
You may not be if
Patients who have received RoActemra/Actemra more than 8 weeks prior to the enrolment visit
Patients who have previously received RoActemra/Actemra in a clinical trial or for compassionate use
Patients who have received treatment with an investigational agent within 4 weeks (or 5 half-lives of the investigational agent, whichever is longer) before starting treatment with RoActemra/Actemra
Patients with a history of autoimmune disease or any joint inflammatory disease other than rheumatoid arthritis
Clareo Health | A Non-Interventional Study in Patients With Rheumatoid Arthritis Who Are Treated With RoActemra/Actemra (Tocilizumab)
